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Background: Heart disease is an important cause of morbidity and mortality in cats,
but there is limited evidence of the benefit of any medication.
Hypothesis: The angiotensin-converting enzyme inhibitor benazepril would delay
the time to treatment failure in cats with heart disease of various etiologies.
Animals: One hundred fifty-one client-owned cats.
Methods: Cats with heart disease, confirmed by echocardiography, with or without
clinical signs of congestive heart failure, were recruited between 2002 and 2005
and randomized to benazepril or placebo in a prospective, multicenter, parallel-
group, blinded clinical trial. Benazepril (0.5-1.0 mg/kg) or placebo was administered
PO once daily for up to 2 years. The primary endpoint was treatment failure. Ana-
lyses were conducted separately for all-cause treatment failure (main analysis) and
heart disease-related treatment failure (supportive analysis).
Results: No benefit of benazepril versus placebo was detected for time to all-cause
treatment failure (P = .42) or time to treatment failure related to heart disease
(P = .21). Hazard ratios (95% confidence interval [CI]) from multivariate analysis for
benazepril compared with placebo were 1.00 (0.57-1.74) for all-cause failure, and
0.99 (0.50-1.94) for forward selection and 0.93 (0.48-1.81) for bidirectional selec-
tion models for heart disease-related failure. There were no significant differences
between groups over time after administration of the test articles in left atrium
diameter, left ventricle wall thickness, quality of life scores, adverse events, or
plasma biochemistry or hematology variables.
Conclusions and Clinical Relevance: Benazepril was tolerated well in cats with
heart disease, but no evidence of benefit was detected.
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1 | INTRODUCTION
Heart disease is an important source of morbidity and mortality in
cats. A variety of medications have been recommended historically
and used in cats with heart disease, including angiotensin-converting
enzyme (ACE) inhibitors (ACEIs), aspirin, beta blockers, clopidogrel,
calcium channel blockers, diuretics, and more recently pimobendan.1-5
However, to our knowledge, the benefit of any pharmaceutical agent
has not been demonstrated in well-controlled prospective clinical tri-
als in cats with heart disease.
At the time of the initiation of the study in 2002, the state of
knowledge was that positive effects of ACEIs on clinical signs and sur-
vival had been demonstrated in humans6,7 and dogs8-10 with conges-
tive heart failure (CHF). In cats, the ACEIs enalapril and benazepril
decreased left ventricular wall thickness of cats with hypertrophic car-
diomyopathy (HCM), but the studies were not well-controlled.11,12 In
addition, there is increased expression of renin in the kidneys of cats
with HCM examined at necropsy, consistent with activation of the
renin-angiotensin-aldosterone system (RAAS).13
Based on the evidence available at the time of starting the study,
it was hypothesized that the ACEI benazepril might have beneficial
effects in cats with heart disease of various etiologies, and not
restricted to cases of HCM.
The main hypothesis of the study was that, compared to placebo,
benazepril would delay the time to treatment failure in cats with heart
disease of various etiologies.
2 | MATERIALS AND METHODS
The study was a prospective, multicenter, parallel-group, randomized,
and blinded clinical trial comparing benazepril with placebo in cats with
heart disease. The study was conducted in compliance with the Proce-
dures and Principles of Good Clinical Practice (VICH GL9, CVMP:
VICH/595/98, 2000), and after approval by company internal review
procedures and the respective regulatory authorities in each country
taking into account animal welfare and ethical guidelines. All owners
had to give their written informed consent before the start of the study.
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The manuscript was prepared after consultation of the CONSORT
statement for reporting of randomized clinical trials.14
2.1 | Study design
All cats were client-owned animals and therefore were fed, housed, and
managed at home as pets. Owners were requested, as far as possible,
not to change the home management of their cats during the trial. On
day 0 (baseline), case history, demographic variables, and results of the
owner assessment and the investigator (veterinarian) clinical examination
were recorded. The cats were scheduled to be examined by the investi-
gator again at weeks 5 (range, ±1), 13 (±1), 26 (±2), and 52 (±4) weeks,
and in some cases also at 78 (±4) and 104 (±4) weeks. The maximum
treatment and follow-up time was initially 1 year, but was extended to
2 years during the study. Systemic systolic blood pressure measured via
Doppler sphygmomanometry, 2-dimensional and M-mode echocardiog-
raphy, electrocardiography, and thoracic radiography were scheduled to
be performed at day 0 and weeks 13, 26, and 52 (plus 78 and 104 weeks
in some cats). No sedation was permitted for 24 hours before an echo-
cardiogram. In order to optimize consistency, investigators were trained
on the techniques used in the study, including echocardiography which
followed published methods.15-17 Blood samples for routine clinical
chemistry and hematology were taken at each visit.
2.2 | Selection of cats
Cats were recruited according to the following inclusion criteria:
1. Cats with heart disease requiring treatment. This included cases with
CHF, and cats without CHF but which had heart disease and struc-
tural changes to the heart that, in the opinion of the investigator,
required treatment. Animals were selected according to the investi-
gator's clinical judgment confirmed by complementary analyses, nota-
bly echocardiography. Underlying cardiac diseases permitted were:
HCM; hypertrophic obstructive cardiomyopathy (HOCM), that is,
outflow obstruction was not an exclusion criterion; dilated cardiomy-
opathy (DCM); restrictive cardiomyopathy (RCM); unclassified cardio-
myopathy (UCM); valvular disease, for example, endocardiosis (but
not endocarditis); and congenital defects not correctable surgically or
that could lead to CHF, for example, mitral dysplasia or aortic steno-
sis. The classification of cases to HCM, HOCM, DCM, RCM, and
UCMwas made according to published criteria.16,17
2. Body weight ≥1.25 to ≤10 kg, to allow dosing with tablets con-
taining 2.5 mg benazepril hydrochloride.
Exclusion criteria for admission were:
1. Congenital heart disease that should be treated surgically, for
example, patent ductus arteriosus, peritoneo-pericardial diaphrag-
matic hernia, or pulmonic stenosis.
2. Congenital cyanotic heart disease.
3. Diabetes mellitus (glycosuria or elevated fructosamine >341 μm/L
or both).
4. Endocarditis or primary pericardial disease.
5. Confirmed heartworm infection (cats were required to be tested
in heartworm endemic areas).
6. Hyperthyroidism (presence of relevant clinical signs or total plasma
thyroxine >55 nmol/L or both).
7. Pulmonary or systemic arterial thrombo-embolism (intracardiac
thrombi were permitted).
8. Systemic hypertension (arterial systolic blood pressure >170 mm Hg).
Blood pressure was measured by Doppler sphygmomanometry, with
a minimum of 3 consistent recordings in a visibly calm cat.
9. Animals intended for breeding or known to be pregnant or lactating.
Cats could be removed from the study after admission because of
the occurrence of the criteria listed below:
1. Hyperthyroidism.
2. Persistent and unacceptably high heart rate, in the clinician's opin-
ion (no threshold value was defined).
3. Need for treatment not permitted in the protocol.
4. Repeated thoracocentesis.
5. Ventricular arrhythmia requiring treatment.
6. Noncompliance with the protocol sufficient to affect the outcome
of the study, including failure to administer the test items.
2.3 | Randomization
After inclusion in the study at day 0, cats were allocated by permuted
block randomization to 1 of the 2 treatment groups in a 1:1 ratio, with
a block size of 4. Separate randomization lists for each investigator
were generated by the statistician using randomization software.
2.4 | Test items
Benazepril was administered as the hydrochloride salt at a minimum
dosage of 0.5 mg/kg (target range of 0.5 to 1 mg/kg) once daily in the
form of palatable divisible tablets containing 2.5 mg benazepril hydro-
chloride (Fortekor 2.5 mg, Elanco Animal Health, Huningue, France).
The placebo tablets had the same appearance and composition as the
benazepril tablets, except that benazepril hydrochloride was replaced
by lactose. The benazepril and placebo tablets were packed into identi-
cal bottles, which were labeled A-D, with 2 codes for each of the items.
Investigators and owners (as well as all study personnel except the
sponsor representative and statistician) were therefore blinded to the
test item administered. The blinding code was not broken in the study.
Owners were instructed to administer the test items, as far as pos-
sible, at the same time each day. The test items could be administered
with or without food.
The dosage of benazepril hydrochloride tested (minimum
0.5 mg/kg) was the same as registered in many countries including the
European Union for the management of proteinuria in cats with
chronic kidney disease.
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The number of tablets dispensed to and returned by the owner
for each cat was checked at each visit. Daily treatment compliance
and ease of administration of the tablets were not assessed.
2.5 | Concomitant medication
All cats with DCM were required to be fed taurine supplementation.
Three drugs with an effect on the cardiovascular system were per-
mitted as concomitant medication: aspirin (at a target dosage of
10 mg/kg/week PO), digoxin (only in cats with DCM as an inotrope at a
target dosage of 0.01 mg/kg PO on alternate days), and furosemide
(dosed to effect, no guidelines or limits were defined, PO but not paren-
teral). Usage and dosages were decided by the investigator as required,
but were not analyzed. Other drugs with a potential action on the car-
diovascular system in cats were not permitted during the study or
within 3 days before inclusion at day 0; including open-label prescrip-
tion of ACEIs, beta blockers, calcium channel blockers, diuretics (other
than furosemide PO), nitroglycerin, and pimobendan.
Other concomitant medications or therapies were permitted pro-
vided that they had no relevant action on the cardiovascular system
or would not interfere with the objectives of the study, or both, for
example, antibiotics or antiparasite products were allowed.
2.6 | Efficacy assessments
The primary endpoint was treatment failure and was defined prospec-
tively in the protocol. Analyses were conducted separately for all-cause
treatment failure (defined as the main analysis) and for heart disease-
related treatment failure (defined as supportive). Heart disease-related
treatment failure (a composite of several sub-endpoints) was defined as
death or euthanasia or withdrawal of the cat from the study because of
worsening of clinical condition (all related to heart disease), persistent
and unacceptably high heart rate (no threshold was defined), repeated
thoracocentesis, or ventricular arrhythmia requiring treatment. All-cause
treatment failure (also a composite) included the heart disease-related
treatment failure reasons plus additionally death or euthanasia or with-
drawal of the cat from the study (all for reasons other than heart dis-
ease), development of hyperthyroidism, or occurrence of a serious
adverse event resulting in the removal of the cat from the study.
The secondary endpoints defined prospectively in the protocol
were the quality of life of the cat assessed by the owner (rated as nor-
mal, medium, poor, or very poor) and the left atrium (LA) diameter and
left ventricle (LV) wall dimension on echocardiography.16,17
In addition, investigators assessed the following variables subjec-
tively using present/absent criteria or 4-point numerical rating scales
(NRS; eg, absent, mild, moderate, or severe): ascites and peripheral
edema on palpation; LA dilation, cardiomegaly, pleural effusion, and pul-
monary edema evident on thoracic radiography (right lateral recumbent
view with or without additional dorsal-ventral view); cardiac and respi-
ratory rate; dyspnea; fluid sounds on pulmonary auscultation; gallop
sound or murmur audible on cardiac auscultation; and cyanotic or pale
mucous membranes. The owners assessed the following variables using
3- or 4-point subjective NRS: appetite, cough, dyspnea, level of activity,
time spent grooming, and ease of administration of the test items.
2.7 | Safety assessments
The safety of the test items was assessed from the investigator clinical
examinations, adverse events reported by the owner, and results of
the clinical chemistry and hematology variables.
2.8 | Statistical analysis
All statistical tests were performed using commercial software (SAS
Software, Version 9.2, Cary, North Carolina). Reported P values are
2-tailed with P < .05 defined as significant. Baseline data were com-
pared between groups using analysis of variance for parametric data
and Fisher's exact test for frequency data.
Time to event analysis was conducted separately for all-cause treat-
ment failure and for heart disease-related treatment failure (defined
earlier). Cats lost from the study for a reason not defined in the proto-
col, or still alive when the study was terminated by the sponsor, were
included in the analysis up until the last time point at which they
remained in the study and were thereafter censored. The Kaplan-Meier
method was used to estimate the median and 95% confidence interval
(CI) time to event, and to generate time to event graphs. The log rank
test with right censoring was used to compare times to event between
groups.
Univariate Cox proportional hazards (CPH) model analysis with
right censoring was performed for each variable to determine the
association between that variable (at baseline) and time to event; the
hazards ratio (HR) and 95% CI were calculated.
The database contained a total of 53 baseline variables from
151 cats, and only 62 cats reached the all-cause failure endpoint. In
order to reduce the risk of overparameterization in the multivariate
analysis, variables were selected for analysis as follows:
1. Heart disease was classified as either congenital or noncongenital
in origin. Noncongenital cardiomyopathy cases were originally
classified as HCM, HOCM, DCM, RCM, or UCM; however, cases
were finally not analyzed according to these subgroups.
2. For echocardiogram variables in which values were available from
2 different techniques, the variable with data from the highest
number of cats was selected. The LA diameter was assessed on
both the short and long axis views, and the end diastolic mean LV
diameter, LV free wall, and LV septum dimensions were based on
the 2-dimensional and M-mode.16,17
3. Correlations for clinical chemistry and hematology variables were
investigated using Spearman rank correlation, and only 1 of the
highly correlated variables was selected. Hematocrit was highly
correlated with red cell count (the correlation coefficient ρ = .79)
and hemoglobin concentration (ρ = .91), therefore hematocrit was
selected. Alkaline phosphatase and alanine aminotransferase activ-
ities were highly correlated (ρ = .70), therefore the former was
selected.
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4. Clinical signs (presence or absence) of reduced appetite, ascites,
crackles, dyspnea, pleural effusion, pulmonary edema, and poor
respiratory character were summarized into a single category, the
presence or absence of CHF signs.
Application of the selection methods described above led to a
smaller subset of 24 variables, which were included in the univariate
CPH analysis (Tables 4 and 6).
For the multivariate analysis, both forward selection and bidirec-
tional selection approaches were used. Models were assessed with or
without forcing treatment into the model; although treatment was not
significant in the univariate analysis, assessment of treatment was the
primary objective of the study. For forward selection, no variables
were selected initially, and candidate variables were tested and added
if they improved the fit of the model (using F tests). Once a variable
entered the model, it was retained. For bidirectional selection, the
5 variables with the lowest P values from the univariate analysis
(Tables 4 and 6) were selected initially (with or without treatment),
and the effect of adding or subtracting the other variables was tested
(using F tests). Introduction of a maximum of 6 variables initially into
the bidirectional selection models complies with the recommendation
to have a minimum of 10 event cases per variable.18
As a final validation of the multivariate CPH models, the best
model approach was employed and confirmed the choice of variables
selected by the forward and bidirectional selection approaches.
The interaction was analyzed between each of the failure end-
points and the presence or absence at baseline of LA diameter
>16 mm (reflecting probable LA enlargement), congenital heart dis-
ease, presence of CHF signs, and presence of dyspnea plus poor qual-
ity of life (representing more severe signs).
Echocardiography, clinical chemistry, and hematology variables
were analyzed longitudinally using repeated measures analysis of
covariance, with baseline as the covariate, and treatment, visit, and
treatment/time interaction as effects. Data were transformed as
appropriate to give the best approximation of a normal distribution.
Scores for clinical signs at each time point and frequencies of
adverse events in the 2 groups after day 0 were compared with Fish-
er's exact test.
A minimum of 100 cats was planned in the protocol, as it was cal-
culated that 50 cats per group would provide 74% power with a 25%
difference between groups for the frequency of occurrence of the pri-
mary endpoint. At least 80% power required an estimated 58 cats per
group. Insufficient data were available before the study, however, to
allow reliable sample size and power estimations.
3 | RESULTS
The number of cats screened was not recorded, but 151 cats were
enrolled into the study at 23 centers (median 5, range 1-27 cats per cen-
ter) between October 2002 and March 2005, and treated up to January
2006. Data from all 151 cats were included in the statistical analysis,
which can therefore be considered an “all-randomized animal” or “intent-
to-treat” analysis data set; 77 received benazepril and 74 received pla-
cebo. No separate “per-protocol” analysis was conducted.
Baseline and demographic data are shown in Table 1, and the fre-
quency of echocardiographic diagnoses in Table 2. A total of 93 cats
(62%) had clinical signs of CHF, whereas 58 (38%) were asymptom-
atic. The frequency of congenital disorders (P = .009) and mean white
blood cell (WBC) counts (P = .04) were significantly higher in the
group of cats randomized to receive benazepril. A flowchart with
study outcomes is shown in Figure 1.
Benazepril hydrochloride at a mean dosage of 0.70 mg/kg (range
0.50 to 1.0 mg/kg) or placebo was administered once daily for up to
2 years.
3.1 | Time to event analysis
Visual examination of the Kaplan-Meier plots indicated no violation of
the proportional hazards assumption (Figures 2 and 3). There were no
clinically relevant differences in conclusions from the time to event
analysis of all-cause or heart disease-related treatment failure.
3.2 | All-cause treatment failure
In the benazepril group, a total of 33 cats reached the all-cause treat-
ment failure endpoint and 44 were censored. In the placebo group, a
total of 29 cats reached the endpoint and 45 were censored. The pro-
portion of cats reaching the endpoint (benazepril 43%, placebo 39%)
or censored was similar in both groups, as were the reasons for failure
(Table 3) and censoring (Figure 1).
For all-cause treatment failure, there was no effect of treatment
(benazepril versus placebo) on time to event with P = .42 in the log
rank test (Figure 2) and univariate CPH model (Table 4). The median
(95% CI) time to event was 553 (196-infinity) days with benazepril
and 648 (215-infinity) days with placebo.
Results of the univariate CPH analysis of the selected baseline
variables are shown in Table 4. Variables significantly (P < .05) associ-
ated with HRs >1 were: LA diameter; WBC, plasma creatinine and
plasma urea; presence of arrhythmias and CHF signs; and reduced
level of activity and poor quality of life. Variables significantly (P < .05)
associated with HRs <1 were: fractional shortening (FS), end diastolic
LV free wall thickness, and interventricular septum thickness.
The 5 variables (those with the lowest P values from the univariate
analysis) included in the bidirectional selection multivariate CPH model
were: LA diameter, CHF signs, FS, WBC, and plasma urea. The forward
selection and bidirectional selection models gave identical results in the
multivariate analysis with 2 variables being significant (P < .05); LA
diameter and presence of CHF signs (Table 5). Treatment was not sig-
nificant (P = 1.0).
There was no significant interaction between the effect of treat-
ment on the risk of all-cause treatment failure and the presence or
absence of a congenital disorder (P = .46), LA diameter >16 or
≤16 mm (P = .24), CHF signs present or absent (P = .57), or presence
of dyspnea plus poor quality of life (P = .22) (details not shown).
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3.3 | Heart disease-related treatment failure
In the benazepril group, a total of 29 cats (38%) reached the heart
disease-related treatment failure endpoint, whereas 48 were cen-
sored (Figure 1 and Table 3). In the placebo group, 22 cats (30%)
reached the endpoint, whereas 52 were censored. There was no sig-
nificant effect of treatment (benazepril versus placebo) on time to
event with P = .21 in the log rank test (Figure 3) and univariate
CPH model (Table 6). The median (95% CI) time to event was
553 (264-infinity) days in the benazepril group, and could not be
determined in the placebo group as the treatment failure rate was
36% at the last event (day 378). The 25% interquartile for time to
event was 123 days in the benazepril and 166 days in the placebo
group.
Results of the CPH univariate analysis of the selected baseline
variables are shown in Table 6. Variables significantly (P < .05) asso-
ciated with HRs >1 were: LA diameter; WBC; plasma urea; presence
of CHF signs, arrhythmias and gallop sound; and poor quality of life.
Variables significantly (P < .05) associated with HRs <1 were: FS,
end diastolic LV free wall and septum thickness, hematocrit, and
plasma albumin.
The 5 variables (those with the lowest P values from the univariate
analysis) included in the bidirectional selection multivariate CPH
model were: LA diameter, FS, CHF signs, arrhythmias, and quality
of life.
In the multivariate CPH analysis (Table 7), FS, plasma sodium,
presence of CHF signs, and arrhythmia were significant in both the
forward and bidirectional selection models (P < .05). Treatment was
not significant in either model (P ≥ .84). Left atrium diameter and
plasma potassium were significant in initial iterations of the forward
selection model, and were therefore retained, but were not significant
in the final model (Table 7).
There was no significant interaction between the effect of
treatment on risk of treatment failure and the presence or absence of
congenital disorder (P = .37), LA diameter >16 or ≤16 mm (P = .32),
CHF signs present or absent (P = .59), or presence of dyspnea plus
poor quality of life (P = .41) (data not shown).
3.4 | Clinical signs
There were no significant differences between the 2 groups after
administration of the test items (ie, at weeks 5-104) for presence/
TABLE 1 Baseline and demographic data
Variable Benazepril (n = 77) Placebo (n = 74) P value
Age (years) 7.8 (4.1) 8.0 (4.1) .74
Sex male:female 59:17 54:19 .70
Congenital disorder yes: no 14:63 3:71 .009
Fractional shortening (%) 45.3 (16.0) 44.2 (16.7) .68
LA diameter (short axis view, mm) 17.2 (5.5) 16.5 (4.7) .39
End diastolic LV diameter (M-mode, mm) 16.2 (6.0) 16.5 (13.7) .85
End diastolic LV free wall thickness (M-mode, mm) 6.98 (2.1) 7.57 (7.8) .54
End diastolic LV septum thickness (M-mode, mm) 5.70 (1.7) 6.92 (8.1) .22
Hematocrit (%) 39.7 (6.8) 40.2 (6.1) .59
White blood cells (109/L) 12.6 (5.9) 10.8 (4.2) .04
Plasma albumin (g/L) 34.2 (3.9) 34.9 (3.3) .22
Plasma calcium (mmol/L) 2.46 (0.19) 2.48 (0.19) .52
Plasma creatinine (μmol/L) 151.9 (56.8) 144.4 (37.4) .35
Plasma phosphate (mmol/L) 1.70 (0.44) 1.60 (1.39) .14
Plasma potassium (mmol/L) 4.54 (1.2) 4.70 (1.1) .41
Plasma sodium (mmol/L) 152.7 (4.8) 153.8 (4.1) .14
Plasma urea (g/L) 0.72 (0.31) 0.65 (0.21) .14
Plasma alkaline phosphatase (U/L) 30.4 (19.9) 34.9 (36.4) .35
CHF signs present:absent 53:24 40:34 .07
Arrhythmia present:absent 14:63 6:68 .09
Gallop sound present:absent 17:60 18:56 .85
Level of activity reduced:not reduced 66:11 64:10 1.0
Quality of life poor:good 28:49 24:50 .73
Notes: P values <.05 are shown in bold. Data are mean (SD) or frequency. P values were calculated by analysis of variance for data reported as mean (SD)
and Fisher's exact test for frequency data.
Abbreviations: CHF, congestive heart failure; LA, left atrium; LV, left ventricle.
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absence or severity of score for any of the clinical signs, including the
quality of life (data not shown).
3.5 | Echocardiography
There were no significant differences between the 2 groups after
administration of the test items (weeks 13-104) in LA diameter or LV
free wall thickness (data not shown).
3.6 | Safety
The number of cats with at least 1 reported adverse event was
42 (77%) with benazepril and 35 (74%) with placebo (P = .42, Fisher's
exact test). The frequency of individual adverse events was similar in
both groups; results for events occurring twice or more in either
group are shown in Table 8. There were no significant differences
between the 2 groups after administration of the test items (weeks
5-104) for any clinical chemistry or hematology variable (data not
shown).
Analyzed (n = 77) 
• Excluded from analysis (n = 0)
Reached all-cause treatment failure endpoint (n = 33) 
Censored (n = 44) 
• Completed study according to protocol (n = 21) 
• Owner consent withdrawn/failure of compliance (n = 8) 
• Withdrawn for other reason (n = 7) 
• Decision of sponsor to stop study (n = 7) 
• Prescription of forbidden concomitant treatment (n = 1) 
Allocated to benazepril (n = 77) 
• Received allocated intervention (n = 77)
• Did not receive allocated intervention (n = 0)
Reached all-cause treatment failure endpoint (n = 
29) 
Censored (n = 45) 
• Completed study according to protocol (n = 23) 
• Withdrawn for other reason (n = 9) 
• Owner consent withdrawn/failure of compliance 
(n = 7) 
• Decision of sponsor to stop study (n = 5) 
• Failure to administer treatment (n = 1) 
Allocated to placebo (n = 74) 
• Received allocated intervention (n = 74)
• Did not receive allocated intervention (n = 0)
Analyzed (n = 74) 




Randomized (n = 151) Enrollment
F IGURE 1 Flowchart showing outcomes of the cats enrolled in the study. The CONSORT (2010) template was used.10 The reasons for
treatment failure are provided in Table 3





(n = 74) P value




Restrictive cardiomyopathy 10 4 .16
Unclassified cardiomyopathy 8 6 .78
Dilated cardiomyopathy 4 7 .36
Mitral valve dysplasia 4 1 .37
Aortic stenosisa 3 0 .25
Ventricular septal defect plus mitral
or tricuspid valve dysplasia
3 0 .25
Ventricular septal defect 2 2 1.0
Atrial septal defect 1 0 1.0
Mitral valve regurgitation 1 0 1.0
Tricuspid valve insufficiency 0 1 .49
Not recorded 1 1 1.0
Notes: Data are number of cases in each group at baseline. P values were
calculated with Fisher's exact test.
aOne case of hypertrophic cardiomyopathy in the benazepril group had in
addition aortic stenosis.
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4 | DISCUSSION
The main result of this study is that we did not detect any beneficial
effect of the ACEI benazepril on the primary endpoint of treatment
failure, or on the secondary echocardiography or quality of life end-
points, in cats with heart disease. Benazepril was tolerated well, with no
differences compared to placebo in the frequency of reported adverse
events or results of plasma chemistry or hematology variables.
Time (days)





































Number of cats remaining in trial  
Day 0 100 200 300 400 500 600 700 800 
Benazepril  77 48 36 32 17 17 8 5 0 
Placebo 74 56 38 36 16 13 8 5 0
F IGURE 2 Kaplan-Meier plot of the cumulative incidence over
time of cats reaching the all-cause treatment failure endpoint. The
number of cats reaching the endpoint/total was 33/77 in the
benazepril and 29/74 in the placebo group. The median time to event
was 553 days in the benazepril and 648 days in the placebo group.






































Number of cats remaining in trial  
0 200 400 600 800
Day 0 100 200 300 400 500 600 700 800
Benazepril 77 48 36 32 17 17 8 5 0
Placebo 74 56 38 36 16 13 8 5 0
F IGURE 3 Kaplan-Meier plot of the cumulative incidence over
time of cats reaching the heart disease-related treatment failure
endpoint. The number of cats reaching the endpoint/total was 29/77
in the benazepril and 22/74 in the placebo group. The 25%
interquartile for time to event was 123 days in the benazepril and
166 days in the placebo group. P = .21 with the log rank test
TABLE 3 Number of cases reaching







Related to heart disease
Death of cat related to heart disease 10 5 .28
Euthanasia of cat related to heart disease 10 4 .16
Cat withdrawn from study because of worsening
of clinical condition related to heart disease
7 11 .32
Repeated thoracocentesis 2 1 1.0
Ventricular arrhythmia requiring treatment 0 1 .49
Persistent and unacceptably high heart rate 0 0 1.0
Total (related to heart disease) 29 22 .39
Other reasons
Cat withdrawn from study for reason other than
heart disease
3 2 1.0
Development of hyperthyroidism 1 2 .62
Death of cat for reason other than heart disease 0 3 .12
Euthanasia of cat for reason other than heart
disease
0 0 1.0
Cat withdrawn from study because of serious
adverse event
0 0 1.0
Total (other) 4 7 .36
Total (all cause, related to heart disease + other) 33 29 .74
Note: P values were calculated with Fisher's exact test.
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The primary endpoint of the study was treatment failure, which was
defined prospectively in the protocol and analyzed using time to event
techniques. All-cause treatment failure was defined as the main analysis,
as it is relevant clinically and in addition maximized the proportion of
cats reaching a defined endpoint (41%) rather than being censored
(59%). Nevertheless, similar results were found, including no detected
benefit of benazepril, when treatment failure related to heart disease
was analyzed.
The relatively low number of cats reaching the defined treatment
failure endpoint (41% for all-cause failure and 34% for heart disease-
related treatment failure) versus being censored is a weakness of the
study, as fewer event cases lowers the power and reliability of the
statistical analysis. Relatively low event rates occur in ACEI studies in
dogs.9,10 Approximately equal numbers of censored and event cases
occurred in a 5 year study in cats with preclinical HCM.19
Further limitations to the study are discussed below. First, the cats
recruited had a wide range of etiologies of heart disease and stages of
progression of disease, and included both asymptomatic and
symptomatic cases. These cases were recruited as the hypothesis for
the study was that an ACEI might have beneficial effects in many of
these cats. However, the relatively high proportion of asymptomatic
cats (58 of 151 cats, 38%), and high variability between cases, could
well have masked possible benefits of benazepril in certain subgroups.
The inclusion criteria permitted inclusion of cats without CHF that, in
the opinion of the investigator, “required treatment” with no further
definition or guideline. We conclude that, in hindsight, this approach
contributed to too many cats without CHF being recruited. Second, it
was not confirmed in all cats that clinical signs attributed to CHF, for
example dyspnea or low appetite, were primarily caused by heart dis-
ease rather than concomitant noncardiac disorders. Third, although
allocation to groups was randomized, the 2 groups were not matched
perfectly at baseline; the group allocated to receive benazepril having
significantly more frequent congenital disorders and higher WBC counts
and numerically, although not significantly, more frequent arrhythmias
(P = .09), clinical signs of CHF (P = .07), and RCM (P = .16). This is the
probable reason why, after treatment, cats receiving benazepril had
TABLE 4 Results of univariate Cox
proportional hazard analysis for the
association among baseline variables, and
treatment, and the risk of reaching the
all-cause treatment failure endpoint
(n = 151 cats)
Variable Hazard ratio
95% confidence interval
P valueLower limit Upper limit
Treatment (benazepril versus placebo) 1.23 0.75 2.02 .42
Age (years) 1.05 0.99 1.12 .08
Sex (male versus female) 1.22 0.65 2.24 .53
Congenital disorder (versus acquired) 0.83 0.38 1.83 .65
Fractional shortening (%) 0.97 0.95 0.99 <.001
LA diameter (short axis view, mm) 1.13 1.08 1.18 <.001
End diastolic LV diameter (M-mode, mm) 1.00 0.98 1.02 .76
End diastolic LV free wall thickness
(M-mode, mm)
0.82 0.70 0.96 .02
End diastolic LV septum thickness
(M-mode, mm)
0.76 0.63 0.91 .003
Hematocrit (%) 0.96 0.93 1.00 .05
White blood cells (109/L) 1.07 1.03 1.11 <.001
Plasma albumin (g/L) 0.94 0.87 1.02 .11
Plasma calcium (mmol/L) 1.17 0.31 4.47 .82
Plasma creatinine (μmol/L) 1.01 1.00 1.01 .004
Plasma phosphate (mmol/L) 1.10 0.62 1.95 .76
Plasma potassium (mmol/L) 1.14 0.91 1.44 .25
Plasma sodium (mmol/L) 0.98 0.93 1.05 .60
Plasma urea (g/L) 3.06 1.64 5.72 <.001
Plasma alkaline phosphatase (U/L) 0.99 0.98 1.01 .33
CHF signs present (versus absent) 3.77 2.00 7.11 <.001
Arrhythmia present (versus absent) 2.78 1.55 4.99 <.001
Gallop sound present (versus absent) 1.69 0.97 2.97 .07
Level of activity reduced (versus not
reduced)
3.85 1.21 12.29 .02
Quality of life poor (versus good) 2.37 1.44 3.91 <.001
Notes: P values <.05 are shown in bold. Variables were analyzed as continuous unless stated.
Abbreviations: CHF, congestive heart failure; LA, left atrium; LV, left ventricle.
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numerically (but not significantly) higher frequencies of death and
euthanasia related to heart disease (Table 3) and shorter times to
events (Figures 1 and 2) compared with the placebo group. Results
from the multivariate CPH models, in which differences in baseline
variables should be accounted for, show that the HRs for treatment
effect were less or equal to 1, consistent with no negative effect of
benazepril. Fourth, management and clinical assessment of cats were
not highly standardized between investigators, and numbers of cases
varied widely between centers (range 1-27) with 14 of the 23 centers
contributing 5 or fewer cases. Fifth, we have no proof that adequate
dosing or inhibition of the RAAS was achieved in the benazepril-
treated cats. We are confident that the dosage of benazepril tested
(range 0.5-1.0 mg/kg) was sufficiently high as it has been shown pre-
viously to effectively inhibit the RAAS in cats, as assessed by inhibi-
tion of plasma ACE activity in healthy cats,20 normalization of
glomerular capillary pressure in cats with experimental renal insuffi-
ciency21 and reduction of proteinuria in cats with chronic kidney dis-
ease.22 However, we have no information that the cats in our study
were dosed correctly with the test items, and did not monitor blood
benazepril concentrations or measure biomarkers (eg, plasma ACE
activity), which could have indicated adequate intake. Finally, the
TABLE 5 Results from the multivariate Cox proportional hazard
analysis for the association among baseline variables, and treatment,
and the risk of reaching the all-cause treatment failure endpoint












1.00 0.57 1.74 1.0
LA diameter (short
axis view, mm)
1.08 1.03 1.14 .004
CHF signs present
(versus absent)
2.70 1.22 5.96 .01
Notes: P values <.05 are shown in bold. Identical results were obtained
with the forward selection and bidirectional selection model fitting
approaches.
Abbreviation: CHF, congestive heart failure; LA, left atrium.
TABLE 6 Results of univariate Cox
proportional hazard analysis for the
association among baseline variables, and
treatment, and the risk of reaching the
heart disease-related treatment failure
endpoint (n = 151 cats)
Variable Hazard ratio
95% confidence interval
P valueLower limit Upper limit
Treatment (benazepril versus placebo) 1.42 0.82 2.48 .21
Age (years) 1.03 0.96 1.10 .45
Sex (male versus female) 1.19 0.61 2.32 .61
Congenital disorder (versus acquired) 1.02 0.46 2.27 .96
Fractional shortening (%) 0.96 0.94 0.98 <.001
LA diameter (short axis view, mm) 1.16 1.11 1.22 <.001
End diastolic LV diameter (M-mode, mm) 1.01 0.99 1.02 .45
End diastolic LV free wall thickness
(M-mode, mm)
0.77 0.64 0.93 .005
End diastolic LV septum thickness
(M-mode, mm)
0.73 0.59 0.89 .002
Hematocrit (%) 0.96 0.92 1.00 .04
White blood cells (109/L) 1.08 1.04 1.13 <.001
Plasma albumin (g/L) 0.92 0.85 1.00 .05
Plasma calcium (mmol/L) 1.07 0.24 4.78 .93
Plasma creatinine (μmol/L) 1.01 1.00 1.01 .06
Plasma phosphate (mmol/L) 1.20 0.64 2.23 .57
Plasma potassium (mmol/L) 1.22 0.97 1.55 .09
Plasma sodium (mmol/L) 0.95 0.89 1.02 .15
Plasma urea (g/L) 3.30 1.69 6.42 <.001
Plasma alkaline phosphatase (U/L) 0.98 0.96 1.00 .06
CHF signs present (versus absent) 6.98 2.97 16.41 <.001
Arrhythmia present (versus absent) 3.68 2.01 6.75 <.001
Gallop sound present (versus absent) 2.11 1.16 3.82 .01
Level of activity reduced (versus not
reduced)
3.19 0.99 10.24 .05
Quality of life poor (versus good) 3.14 1.81 5.47 <.001
Notes: P values <.05 are shown in bold. Variables were analyzed as continuous unless stated.
Abbreviations: CHF, congestive heart failure; LA, left atrium; LV, left ventricle.
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study is old; the cats were treated from 2002 to 2006 and the manu-
script was only completed in 2016. The main reason the manuscript
was delayed was that it was judged initially that the study might not
be worth publishing with (exclusively) univariate time to event analy-
sis and the limitations discussed above. Later, after awareness of the
importance of publishing negative results had increased, it took sev-
eral years to agree on variable selection and perform valid multivariate
time to event analysis.
The study had important flaws; the main motivation for publication
is disclosure of the (negative efficacy) results, but the results do contrib-
ute knowledge on the natural history of cats with heart disease. Despite
the limitations of the study, the results suggest that the ACEI benazepril
at the tested dosage has no or at best only a small benefit on time to
treatment failure in many cats with heart disease. Data published before
and after completion of the study do not provide strong evidence for a
benefit of ACEIs in cats with HCM. Evidence of RAAS activation in cats
with HCM is weak; renin expression is increased in kidneys of cats with
HCM at necropsy13 and abnormally high plasma aldosterone concentra-
tions occur in approximately half of Maine Coon cats with asymptom-
atic HCM.23 Although the ACEIs enalapril and benazepril had positive
effects on echocardiography variables in small not well-controlled stud-
ies of cats with HCM,11,12 the ACEI ramipril and the aldosterone antag-
onist spironolactone did not improve diastolic function or left
ventricular mass in Maine Coon cats with asymptomatic HCM.23,24 No
significant differences between effects of benazepril and diltiazem
occurred in cats with HCM.25 Interim results of a prospective field study
in cats with diastolic heart failure including the ACEI enalapril were pub-
lished as an abstract in 2003.26
The study was designed to provide 74% power with a 25% differ-
ence between groups for the primary endpoint with a minimum of
100 cats recruited. Although more cases were recruited, the power of
the study was impaired by the relatively low number of cats (n = 62)
which reached the defined failure endpoints rather than being censored.
Post hoc power analysis confirmed that with 75 cats per group, as rec-
ruited, 80% power would be achieved if the difference between groups
was at least 25% (30/75 for benazepril versus 49/75 for placebo). The
lack of observed significant differences between groups therefore does
not exclude the possibility of a smaller effect of benazepril or effects in
certain subgroups of cats, such as those presented in CHF.
TABLE 7 Results from the multivariate Cox proportional hazard analysis for the association among baseline variables, and treatment, and the
risk of reaching the heart disease-related treatment failure endpoint (n = 151 cats)
Model fitting approach/variable Hazard ratio
95% confidence interval
P valueLower limit Upper limit
Forward selection
Treatment (benazepril versus placebo) 0.99 0.50 1.94 .97
Fractional shortening (%) 0.97 0.95 0.99 .007
LA diameter (short axis view, mm) 1.04 0.97 1.11 .29
Plasma potassium (mmol/L) 1.19 0.97 1.48 .10
Plasma sodium (mmol/L) 0.92 0.87 0.98 .008
CHF signs present (versus absent) 5.10 1.66 15.67 .004
Arrhythmia present (versus absent) 2.84 1.29 6.26 .009
Bidirectional selection
Treatment (benazepril versus placebo) 0.93 0.48 1.81 .84
Fractional shortening (%) 0.96 0.95 0.98 <.001
Plasma sodium (mmol/L) 0.92 0.86 0.98 .008
CHF signs present (versus absent) 5.34 1.83 15.60 .002
Arrhythmia present (versus absent) 3.52 1.71 7.26 <.001
Note: P values <.05 are shown in bold.
Abbreviations: CHF, congestive heart failure; LA, left atrium.
TABLE 8 Frequency of reported adverse events occurring in two






(n = 74) P value
Dyspnea 6 4 .75
Vomiting 2 6 .16
Abscess 2 1 1.0
Syncope 2 1 1.0
Tachypnea 2 1 1.0
Weakness 2 1 1.0
Cystitis 2 0 .50
Diarrhea 2 0 .50
Skin infection 1 2 .62
Collapse 0 2 .24
Ocular discharge 0 2 .24
Note: P values were calculated with Fisher's exact test.
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Although it was not 1 of the predefined objectives of the study,
we were able to determine some prognostic variables for cats with
heart disease. In the CPH multivariate analysis, LA diameter and pres-
ence of CHF signs were significantly associated with increased risk to
reach the all-cause treatment failure endpoint. For the heart disease-
related treatment failure endpoint, FS, plasma sodium, and the pres-
ence of arrhythmias and CHF signs were significant. These results are
consistent with previous retrospective studies in cats with HCM,
which identified age, LA dysfunction, LA enlargement, low LV systolic
function, LV hypertrophy, and presence of CHF signs at diagnosis as
risk factors in cats with HCM.19,27-32
5 | CONCLUSIONS
The ACEI benazepril was tolerated well in cats with heart disease, but
we found no evidence of benefit. In view of the limitations of the
study, however, it is not possible to make a definitive conclusion that
ACEIs have no beneficial actions in all etiologies and stages of heart
disease in cats. Nevertheless, there was no significant interaction
between the effect of treatment with benazepril on the risk of treat-
ment failure for any of the analyses, including the presence or absence
of CHF signs. Further adequately designed and powered studies are
recommended, including in selected subgroups of cats with specific
etiologies of heart disease.
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